LOGO
LOGO

FDA Calendar - Camurus AB

Company Name Camurus AB
CAMX.ST
Drug Name Oclaiz (resubmitted NDA)
Event Name FDA decision on Oclaiz for the treatment of patients with acromegaly
Event Date 06/10/2026
Outcome Date
Outcome Pending
Drug Status FDA issued a complete response letter for Oclaiz for the treatment of patients with acromegaly on Oct.22, 2024.
Rival Drugs
Market Potential
Other Approvals In August 2025, Oczyesa was approved for the treatment of acromegaly in the UK.

In July 2025, Oczyesa received marketing authorization for treatment of acromegaly in the EU.
News
Return to FDA Calendar
RELATED NEWS (Camurus AB)
Editors Pick
airfranceairbus 22052026 lt

French Court Rules Air France And Airbus Guilty In 2009 Plane Crash; Companies To Appeal

May 22, 2026 05:33 ET
walmart 21052026 lt

Walmart Sees Growth In Q2, Backs FY27 Outlook After Strong Q1; Stock Down

May 21, 2026 08:33 ET
tjx 20052026 lt

TJX Sees Positive Q2, Lifts FY27 View After Higher Q1; Raises Buyback Range; Stock Gains

May 20, 2026 08:14 ET
samsungoogle 20052026 lt

Samsung, Google Debut AI Eyewear

May 20, 2026 03:51 ET
Copyright © 2026 RTTNews. All rights reserved. By using this site, you agree to the Terms of Service. About Us   |   Contact Us   |   Privacy   |   Sitemap